Sydney, AUSTRALIA, April 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback